Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

被引：0
|
作者：
Nicola Ferrante
Daniela Ritrovato
Rossella Bitonti
Gianluca Furneri
机构：
[1] Novartis Farma S.p.A,
[2] EBMA Consulting,undefined
来源：
BMC Health Services Research | / 22卷
关键词：
Brolucizumab; Neovascular age-related macular degeneration; nAMD; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Aflibercept for neovascular age-related macular degeneration
    Sarwar, Salman
    Clearfield, Elizabeth
    Soliman, Mohamed Kamel
    Sadiq, Mohammad Ali
    Baldwin, Andrew J.
    Hanout, Mostafa
    Agarwal, Aniruddha
    Sepah, Yasir J.
    Do, Diana V.
    Quan Dong Nguyen
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [22] COST UTILITY ANALYSIS OF AFLIBERCEPT, RANIBIZUMAB, AND BEVACIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Lin, C. W.
    Hay, J.
    VALUE IN HEALTH, 2014, 17 (03) : A287 - A287
  • [23] Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    Stewart, Michael W.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2013, 5 : 81 - 93
  • [24] Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    He, Lingmin
    Silva, Ruwan A.
    Ayoub, Noel
    Moshfeghi, Darius M.
    Leng, Theodore
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (05): : 542 - 549
  • [25] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yasuo Yanagi
    Kanji Takahashi
    Tomohiro Iida
    Fumi Gomi
    Junko Morii
    Eriko Kunikane
    Taiji Sakamoto
    Ophthalmology and Therapy, 2023, 12 : 2005 - 2021
  • [26] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
    Yanagi, Yasuo
    Takahashi, Kanji
    Iida, Tomohiro
    Gomi, Fumi
    Morii, Junko
    Kunikane, Eriko
    Sakamoto, Taiji
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (04) : 2005 - 2021
  • [27] Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
    Yannuzzi, Nicolas A.
    Freund, K. Bailey
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 1323 - 1329
  • [28] Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid
    Singh, Rishi P.
    Jhaveri, Chirag
    Wykoff, Charles C.
    Gale, Richard P.
    Staurenghi, Giovanni
    Iida, Tomohiro
    Koh, Adrian
    Guruprasad, B.
    Gedif, Kinfemichael
    Singer, Michael
    OPHTHALMOLOGY RETINA, 2022, 6 (05): : 377 - 386
  • [29] Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
    Enriquez, Ana Bety
    Baumal, Caroline R.
    Crane, Ashley M.
    Witkin, Andre J.
    Lally, David R.
    Liang, Michelle C.
    Enriquez, Jose Ramon
    Eichenbaum, David A.
    JAMA OPHTHALMOLOGY, 2021, 139 (04) : 441 - 448
  • [30] The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective
    van Asten, Freekje
    Michels, Charlotte T. J.
    Hoyng, Carel B.
    van der Wilt, Gert Jan
    Klevering, B. Jeroen
    Rovers, Maroeska M.
    Grutters, Janneke P. C.
    PLOS ONE, 2018, 13 (05):
12345